Drawing on a deep understanding of the underlying causes of some of the most challenging diseases, Ichnos Sciences is pursuing truly disease-centric therapies in oncology, autoimmune disease, and pain management. We strive to develop novel assets and find new answers to some of medicine’s greatest challenges. Because the world is waiting.

Our path towards disease centric therapies

ONCOLOGY

Compound*
Mechanism
Preclinical
IND-Enabling
PHASE 1
PHASE 2
PHASE 3
ISB 1302
HER 2 x CD 3
BEAT® bispecific antibody
Metastatic HER2 + Breast Cancer
 
ISB 1342
CD 38 x CD 3
BEAT® bispecific antibody
Relapsed/Refractory Multiple Myeloma (MM)
 
ISB 1908
T cell engager
 
 
2H 2020
 
ISB 1909
T cell engager
 
 
 
1H 2021
ISB 1442
Innate immune engager
 
 
2H 2020
 
ISC XXXX
HPK1 Inhibitor
 
 
2H 2020
 

Autoimmune Disease

Compound*
Mechanism
Preclinical
IND-Enabling
PHASE 1
PHASE 2
PHASE 3
ISB 830
OX 40 Antagonist
Monoclonal antibody
Atopic Dermatitis (AD)
 
ISB 880
Targeted anti-inflammatory therapy
 
 
2H 2020
 

Pain

Compound*
Mechanism
Preclinical
IND-Enabling
PHASE 1
PHASE 2
PHASE 3
ISC 17536
TRPA1 antagonist
Diabetic Peripheral Neuropathy (DPN)
 

ONCOLOGY Compounds*

ISB 1302
HER 2 x CD 3
BEAT® bispecific antibody
Metastatic HER2 + Breast Cancer
Phase 1
ISB 1342
CD 38 x CD 3
BEAT® bispecific antibody
Relapsed/Refractory Multiple Myeloma (MM)
Phase 1
ISB 1908
T cell engager
Preclinical
2H 2020
IND enabling studies
ISB 1909
T cell engager
Preclinical
1H 2021
IND enabling studies
ISB 1442
Innate immune engager
Preclinical
2H 2020
IND enabling studies
ISC XXXX
HPK1 Inhibitor
Preclinical
2H 2020
IND enabling studies

Autoimmune Disease Compounds*

ISB 830
OX 40 Antagonist
Monoclonal antibody
Atopic Dermatitis (AD)
Phase 2
ISB 880
Targeted anti-inflammatory therapy
Preclinical
2H 2020
IND enabling studies

Pain Compounds*

ISC 17536
TRPA1 antagonist
Diabetic Peripheral Neuropathy (DPN)
Phase 2

*Assets that were previously identified as GBR and GRC are now identified as ISB (for biologics) and ISC (for small molecules), respectively.

View Career Opportunities

United States

Switzerland

India

You are now leaving the Ichnos Sciences Inc. website.


The link you have selected is provided for your convenience, and Ichnos is not responsible for content, privacy or security issues associated with your visit to external websites.


Cancel Continue

You are now leaving the Ichnos Sciences Inc. website.


The link you have selected is provided for your convenience, and Ichnos is not responsible for content, privacy or security issues associated with your visit to external websites.


Cancel Continue